Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Glioma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma 1Lung Neoplasms 1Laryngeal Neoplasms 1Histiocytosis, Langerhans-Cell 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1

Interventions

pembrolizumab 42Nivolumab 13Carboplatin 11Cyclophosphamide 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Cisplatin 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × trametinib × Gynecologic × Clear all
NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

GlaxoSmithKline

Phase 1 Completed
240 enrolled
BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡